2Boubaya A, Gomez E, Guerder A, et al. Bronchioloalveolar carcino- ma: an exceptional cause of diffuse lung disease in a patient with acute myeloid leukemia [ J ]. Rev Mal Respir, 2014, 31 ( 3 ) : 259 - 262.
2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J ned,2002,346(2) :92-98.
3Sandier A,Gray R,Perry MC,et al. Paclitaxelcarboplatinalone or with bevacizumab for non-smallcell lung cancer [J]. N Engl J Med,2006,355(24) :2542-2550.
4Esteban E,Casillas M,Cassinello A. Pemetrexed in first- line treatment of non-small cell lung cancer [J]. Cancer Treatment Reviews, 2009,35 (04) : 364-373.
5Hanna N,Shepherd FA,Fossella FV,et al. Randomized phase m trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004,22(9) : 1589-1597.
6Scagliotti GV, Parikh P, von Pawel J, et al. Phase m study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with ad- vanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008,26(21 ) : 3543-3551.
7Zinner RG,Novello S,Peng G,et al. Comparison of patient outcomes according to histology anaong pemetrexed-treated patients with stage m B/IV non-small-cell lung cancer in two phase trials [J]. Clinical Lung Cancer,2010,11 (2): 126-13l.
8David R,Spigel MD,John D,et al. Phase H study of bi- weekly pemetrexed and gemcitabine in patients with pre- viously untreated advanced non-small cell lung cancer [ J ]. J Thorac Oncol, 2010,5 (6): 841-845.
9Zheng Z,Li X,Schell MJ,et al. Thymidylate synthase in situ protein expression and survival in stage I non-small- cell lung cancer[J]. Cancer,2008,112(12) :2765-2773.
10Grcnberg BH,Bremnes RM,Flctten O,et al. Phase IU study by the Norwegian lung cancer study group:pcme- trexed plus carhoplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non- small-cell lung cancer [J]. J Clin Oncol,2009,27(19): 3217-3224.
